Analyzing Efficacy Outcomes from the Phase 2 Study of Single-Agent Tazemetostat As Third-Line Therapy in Patients with Relapsed or Refractory Follicular Lymphoma to Identify Predictors of Response

被引：3
|
作者：
Salles, Gilles
Tilly, Herve
Chaidos, Aristeidis
Mckay, Pam
Phillips, Tycel J.
Assouline, Sarit E.
Batlevi, Connie Lee
Campbell, Philip
Ribrag, Vincent
Damaj, Gandhi Laurent
Dickinson, Michael
Jurczak, Wojciech
Kazmierczak, Maciej
Opat, Stephen
Radford, John A.
Schmitt, Anna
Whalen, Jennifer
Hamlett, Anthony
Kamp, Beth
Adib, Deyaa
Morschhauser, Franck
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-137245
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：6
相关论文
共 50 条
  • [1] Analyzing Efficacy Outcomes From the Phase 2 Study of Single-Agent Tazemetostat as Third-Line Therapy in Patients With Relapsed or Refractory Follicular Lymphoma to Identify Predictors of Response
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 2 - 3
  • [2] Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial
    Bartlett, Nancy L.
    Costello, Brian A.
    LaPlant, Betsy R.
    Ansell, Stephen M.
    Kuruvilla, John G.
    Reeder, Craig B.
    Thye, Lim S.
    Anderson, Daniel M.
    Krysiak, Kilannin
    Ramirez, Cody
    Qi, Jing
    Siegel, Barry A.
    Griffith, Malachi
    Griffith, Obi L.
    Gomez, Felicia
    Fehniger, Todd A.
    BLOOD, 2018, 131 (02) : 182 - 190
  • [3] Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma
    Morschhauser, Franck
    Tilly, Herve
    Chaidos, Aristeidis
    Phillips, Tycel J.
    Ribrag, Vincent
    Campbell, Philip
    Laurent, Damaj Gandhi
    Jurczak, Wojciech
    McKay, Pamela
    Opat, Stephen
    Radford, John
    Whalen, Jennifer
    Rajarethinam, Anand
    Navia, Susan Benedict
    Adib, Deyaa
    Salles, Gilles
    BLOOD, 2019, 134
  • [4] Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
    Morschhauser, Franck
    Tilly, Herve
    Chaidos, Aristeidis
    McKay, Pamela
    Phillips, Tycel
    Assouline, Sarit
    Batievi, Connie Lee
    Campbell, Phillip
    Ribrag, Vincent
    Damaj, Gandhi Laurent
    Dickinson, Michael
    Jurczak, Wojciech
    Kazmierczak, Maciej
    Opat, Stephen
    Radford, John
    Schmitt, Anna
    Yang, Jay
    Whalen, Jennifer
    Agarwal, Shefali
    Adib, Deyaa
    Salles, Gilles
    LANCET ONCOLOGY, 2020, 21 (11): : 1433 - 1442
  • [5] Efficacy and Safety of Single-Agent Zandelisib Administered By Intermittent Dosing in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Final Results of the Tidal Phase 2 Study
    Zelenetz, Andrew D.
    Jurczak, Wojciech
    Ribrag, Vincent
    Linton, Kim M.
    Collins, Graham P.
    Bishton, Mark
    Lopez Jimenez, Javier
    Dholaria, Bhagirathbhai
    Mengarelli, Andrea
    Phillips, Tycel J.
    Sungala, Nagendra Prasad
    Chan, Henry
    Musuraca, Gerardo
    Sheehy, Oonagh
    Yan, Junyi
    Xu, Weiming
    Azoulay, Michel
    Zinzani, Pier Luigi
    BLOOD, 2022, 140 : 3595 - 3597
  • [6] Single-Agent Ibrutinib Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Phase 2 Study
    Noy, Ariela
    de Vos, Sven
    Thieblemont, Catherine
    Martin, Peter
    Flowers, Christopher
    Morschhauser, Franck
    Collins, Graham P.
    Ma, Shuo
    Coleman, Morton
    Peles, Shachar
    Smith, Stephen
    Smith, Alina
    Munneke, Brian
    Dimery, Isaiah
    Beaupre, Darrin
    Chen, Robert W.
    BLOOD, 2016, 128 (22)
  • [7] Interim Update from a Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
    Pagel, John
    Morschhauser, Franck
    Herve, Tilly
    Chaidos, Aristeidis
    Phillips, Tycel
    Ribrag, Vincent
    Campbell, Phillip
    Fruchart, Christophe
    Jurczak, Wojciech
    McKay, Pamela
    Opat, Stephen
    Radford, John
    McDonald, Alice
    Howell, Haley
    Newberry, Kate
    Woodruff, Mark
    Clawson, Alicia
    Larus, John
    Blakemore, Stephen
    Miao, Harry
    Salles, Gilles
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S278 - S279
  • [8] Phase II study of single-agent copanlisib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
    Lenz, Georg
    Hawkes, Eliza
    Verhoef, Gregor
    Haioun, Corinne
    Thye, Lim Soon
    Heo, Dae Seog
    Ardeshna, Kirit
    Chong, Geoffrey
    Christensen, Jacob Haaber
    Shi, Vivian
    Lippert, Susanne
    Niemeyer, Florian
    Piraino, Paolo
    Pena, Carol Elaine
    Buvaylo, Viktoriya
    Childs, Barrett H.
    Gorbatchevsky, Igor
    Salles, Gilles A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [9] Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
    Budde, Lihua E.
    Sehn, Laurie H.
    Matasar, Matthew
    Schuster, Stephen J.
    Assouline, Sarit
    Giri, Pratyush
    Kuruvilla, John
    Canales, Miguel
    Dietrich, Sascha
    Fay, Keith
    Ku, Matthew
    Nastoupil, Loretta
    Cheah, Chan Yoon
    Wei, Michael C.
    Yin, Shen
    Li, Chi-Chung
    Huang, Huang
    Kwan, Antonia
    Penuel, Elicia
    Bartlett, Nancy L.
    LANCET ONCOLOGY, 2022, 23 (08): : 1055 - 1065
  • [10] Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study
    Salles, Gilles
    Schuster, Stephen J.
    de Vos, Sven
    Wagner-Johnston, Nina D.
    Viardot, Andreas
    Blum, Kristie A.
    Flowers, Christopher R.
    Jurczak, Wojciech J.
    Flinn, Ian W.
    Kahl, Brad S.
    Martin, Peter
    Kim, Yeonhee
    Shreay, Sanatan
    Will, Matthias
    Sorensen, Bess
    Breuleux, Madlaina
    Zinzani, Pier Luigi
    Gopal, Ajay K.
    HAEMATOLOGICA, 2017, 102 (04) : E156 - E159
12345